drug_type
RELEVANT_DRUG
intervention_type
Drug (monoclonal antibody, biologic)
drug_description
Chimeric IgG1 monoclonal antibody against TNF-α; neutralizes soluble and transmembrane TNF-α, can induce apoptosis of activated effector T cells/monocytes, and suppresses NF-κB–driven cytokines.
nci_thesaurus_concept_id
C1789
nci_thesaurus_preferred_term
Infliximab
nci_thesaurus_definition
A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)
drug_mesh_term
Infliximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous, Subcutaneous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody that binds and neutralizes soluble and transmembrane TNF-alpha, blocking TNF signaling; can induce apoptosis of activated effector T cells/monocytes and suppress NF-kB–driven proinflammatory cytokines to reduce inflammation.
drug_name
Infliximab
nct_id_drug_ref
NCT06604728